Edwards Q4 sales $1.39B (+9%), adjusted EPS $0.59; reiterates 2025 guidance

Edwards Lifesciences Corp

2024-FY EPS reported $6.97 revenue$5,439,500,000

Q4 sales $1.39B (+9% YoY); TAVR $1.04B (+6%), TMTT $105M (+88%).
GAAP EPS $0.58; adjusted EPS $0.59; full-year sales from continuing ops $5.5B.
2025 guidance reaffirmed: constant currency sales growth 8-10%, adjusted EPS $2.40-$2.50.
Expect mid-year FDA approval for asymptomatic TAVR; presented EARLY TAVR and TRISCEND II trials.
Cash $3.0B; debt $600M; adjusted gross margin 79.0%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.